NCT01534962View on ClinicalTrials.gov

Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion

PHASE2CompletedINTERVENTIONAL

Enrollment

241

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

March 31, 2014

Conditions

Persistent Atrial Fibrillation

Interventions

DRUG

Ranolazine

Oral administration, BID; for a maximum of 112 days.

DRUG

Ranolazine

Oral administration, BID; for a maximum of 112 days.

DRUG

Ranolazine

Oral administration, BID; for a maximum of 112 days.

DRUG

Placebo

Oral administration, BID; for a maximum of 112 days.

Trial Locations (4)

27100

FONDAZIONE IRCCS, Dip. Cardiotoracovascolare (U.C.C.), Pavia

37075

Universitätsmedizin Göttingen (UMG), Kardiologie und Pneumologie, Göttingen

08036

Hospital Clínic i Provincial de Barcelona, Servicio de Cardiología-Sección de Arritmias, Barcelona

SW17 0RE

St. George's University of London, London

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Menarini Group

INDUSTRY

NCT01534962 - Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion | Biotech Hunter | Biotech Hunter